Glaucoma is a common, potentially blinding pathology, threatening patients' autonomy and quality of life. The main aim of treatment is to lower intraocular pressure (IOP) in order to slow nerve fiber loss as much as possible, leading to alterations in the visual field and even reduced visual acuity. To achieve this drop in pressure, there are, of course, hypotonizing eye drops, trabeculoplasty with Laser Selecta (SLT) or filtering surgery (trabeculectomy, deep non-perforating sclerectomy, insertion of drainage devices). Laser Selecta specifically targets pigmented trabecular meshwork cells without damaging adjacent structures, and is thought to act via three mechanisms: distension of Schlemm's canal, reorganization of trabecular meshwork cells and stimulation of extracellular matrix production. Its efficacy has been demonstrated in several studies, with a 20-30% reduction in intraocular pressure in patients who have never undergone surgery. Few studies have investigated the efficacy of SLT in patients who have already undergone filtering surgery. The aim of this study is therefore to determine the efficacy of SLT in previously operated patients whose intraocular pressure remains insufficiently controlled.

Inclusion Criteria:

• Patients aged ≥ 18 years
• Patients who have undergone filtering surgery such as trabeculectomy, deep non-perforating sclerectomy, or placement of a Xen®-type device
• Patients who have undergone laser SLT
• Patient with primary open-angle glaucoma, exfoliative glaucoma or pigmentary glaucoma
• Insufficiently controlled intraocular pressure.

Exclusion Criteria: - Patients under guardianship or curatorship

• Patient deprived of liberty
• Patient objecting to the use of his or her data for this research
• Patient with angle-closure glaucoma
• Patient having undergone any other type of eye surgery except cataract surgery

Patient undergoind SLT with insufficiently controlled IOP after filtering surgery